BMO Capital Markets Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its price objective cut by analysts at BMO Capital Markets from $18.00 to $15.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “market perform” rating on the life sciences company’s stock. BMO Capital Markets’ price objective indicates a potential upside of 12.61% from the stock’s current price.

Several other analysts also recently commented on IART. Wells Fargo & Company set a $15.00 target price on shares of Integra LifeSciences in a report on Saturday. Truist Financial raised shares of Integra LifeSciences to a “hold” rating in a report on Thursday, October 1st. Wall Street Zen downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup reaffirmed a “neutral” rating and issued a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. Finally, UBS Group started coverage on Integra LifeSciences in a research note on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and an average price target of $17.29.

Integra LifeSciences Stock Up 0.2%

IART stock opened at $13.32 on Monday. Integra LifeSciences has a 1-year low of $8.70 and a 1-year high of $20.49. The business’s 50 day simple moving average is $16.43 and its 200 day simple moving average is $15.25. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75. The firm has a market capitalization of $1.04 billion, a PE ratio of -147.98, a PEG ratio of 0.69 and a beta of 1.21.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The business had revenue of $418.76 million during the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, research analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently bought and sold shares of the business. Paradigm Capital Management Inc. NY bought a new position in shares of Integra LifeSciences during the second quarter worth approximately $61,766,000. Wellington Management Group LLP boosted its stake in shares of Integra LifeSciences by 12.4% in the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after buying an additional 160,814 shares during the period. Bank of America Corp DE boosted its stake in shares of Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company’s stock valued at $13,325,000 after buying an additional 589,408 shares during the period. Invenomic Capital Management LP grew its position in Integra LifeSciences by 78.3% during the fourth quarter. Invenomic Capital Management LP now owns 1,055,941 shares of the life sciences company’s stock worth $13,115,000 after buying an additional 463,729 shares in the last quarter. Finally, Glenmede Trust Co. NA increased its stake in Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company’s stock worth $9,276,000 after acquiring an additional 211,774 shares during the period. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.